(Q58235736)

English

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

scientific article published on 24 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

0 references

chronic hepatitis B

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

6

object named as

Man-Fung Yuen

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Danny Ka-Ho Wong

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Fung-Yu Huang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

0 references

publication date

24 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

58

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

923-931

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Future prevention and treatment of chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

21 January 2018

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

7 January 2021

based on heuristic

inferred from DOI database lookup

A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

7 January 2021

based on heuristic

inferred from DOI database lookup

Index for rating diagnostic tests

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26376

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.26376

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23468172%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58235736&oldid=1753034185"